Breakthrough T1D

https://www.breakthrought1d.org/

Breakthrough T1D, formerly known as JDRF (Juvenile Diabetes Research Foundation), is a leading global nonprofit organization dedicated to type 1 diabetes (T1D) research and advocacy. Founded in 1970 by parents of children with T1D, its mission is to accelerate life-changing breakthroughs to cure, prevent, and treat type 1 diabetes and its complications. The organization's headquarters are located in New York, New York, US.

Breakthrough T1D primarily funds and drives research aimed at restoring the body's ability to produce insulin, preventing T1D onset, and providing insulin independence, while also working to improve the daily lives of those affected. The organization supports the development of new therapies and treatments, including advancements in Artificial Pancreas (AP) Systems, Continuous Glucose Monitors (CGM), and drugs like Tzield. Beyond research, it engages in significant advocacy efforts, championing federal funding for T1D research through programs like the Special Diabetes Program, influencing policy, and working to ensure access to affordable insulin and critical medical advancements.

In June 2024, the organization rebranded from JDRF to Breakthrough T1D to better reflect its focus on individuals of all ages living with T1D and its leadership in accelerating scientific discovery and therapeutic development. Aaron J. Kowalski, Ph.D., who lives with T1D himself, serves as the Chief Executive Officer. The organization continues to be a major force in the T1D community, having invested over $2.1 billion in diabetes research since its inception and recently announcing new International Board of Directors leadership with Karen Shishino Jordan as Chair and Carlton McMillan as Vice Chair, effective July 1, 2026.

Latest updates

Tzield Approval Expands to Younger T1D Patients, Broadening Disease-Modifying Market

Event summary

  • Breakthrough T1D (formerly JDRF) received FDA approval for Sanofi’s Tzield (teplizumab-mzwv) to delay the onset of type 1 diabetes (T1D) in children ages one and older.
  • Tzield was initially approved in 2022 for individuals 8 and older to delay progression from stage 2 to stage 3 T1D.
  • The drug is the first disease-modifying therapy for T1D, targeting the autoimmune process.
  • Breakthrough T1D emphasizes the importance of early detection and screening for T1D to maximize the benefit of Tzield.

The big picture

The expanded approval of Tzield represents a significant shift towards proactive T1D management, moving beyond symptom treatment to disease modification. This approval validates the disease-modifying approach and creates a new market segment for therapies targeting early-stage T1D. While the global T1D population is relatively small (9.5 million), the potential for long-term cost savings and improved patient outcomes makes this a strategically important area for pharmaceutical investment.

What we're watching

Adoption Rate
The speed of adoption among pediatric endocrinologists and families will be crucial for Tzield’s market penetration, contingent on awareness campaigns and reimbursement coverage.
Screening Expansion
The success of Tzield hinges on expanding early detection screening programs, which will require investment and collaboration between Breakthrough T1D, healthcare providers, and potentially government agencies.
Competitive Landscape
Other companies are likely to accelerate development of alternative disease-modifying therapies for T1D, creating potential competitive pressure on Sanofi and Breakthrough T1D’s market share.

Breakthrough T1D Board Shakeup Signals Focus on Innovation Amidst Therapy Advances

Event summary

  • Karen Shishino Jordan has been named Chair of Breakthrough T1D’s International Board of Directors (IBOD), succeeding an unnamed predecessor.
  • Carlton McMillan has been appointed Vice Chair of the IBOD, alongside Jordan.
  • Jordan, who was diagnosed with T1D in 2023, previously held leadership roles including Finance and Investment Committee Chair.
  • McMillan, whose wife was diagnosed with T1D at age five, spearheaded a corporate partnership between Airbnb and Breakthrough T1D.
  • Both appointments occur during a period of accelerating scientific progress in T1D therapies.

The big picture

The leadership transition at Breakthrough T1D coincides with a period of rapid innovation in T1D therapies, including potential cures and preventative measures. The appointments of Jordan and McMillan, both with deep personal and professional connections to the disease, signal a strategic emphasis on financial discipline and expanded partnerships to capitalize on this momentum. The organization's influence extends globally, impacting millions of individuals and driving significant research funding.

What we're watching

Governance Dynamics
Jordan’s dual experience as a T1D patient and finance expert suggests a heightened focus on financial stewardship and patient-centric research priorities.
Partnership Strategy
McMillan’s prior success with Airbnb indicates a potential shift towards more robust corporate partnerships to expand fundraising and awareness efforts.
Research Alignment
The board’s focus on a ‘golden age of advanced medicine’ implies increased scrutiny of research investments and a potential acceleration of clinical trial timelines.

Breakthrough T1D Honors Indian Princess for Diabetes Advocacy

Event summary

  • Breakthrough T1D (formerly JDRF) awarded Princess Padmaja Kumari Parmar of Udaipur the Mary Tyler Moore Award on March 16, 2026.
  • The award was presented during Breakthrough T1D on the Hill, a lobbying event in Washington, D.C.
  • Princess Padmaja has expanded access to T1D care in India through government programs and specialized clinics.
  • The Mary Tyler Moore Award recognizes individuals who champion positive change for the T1D community.
  • Princess Padmaja's father passed away one year prior to receiving the award.

The big picture

This recognition underscores the growing importance of international advocacy in addressing healthcare disparities. Breakthrough T1D's focus on expanding access to care in developing nations signals a strategic shift beyond its traditional US-centric research and advocacy model. The organization's reliance on high-profile figures like Princess Padmaja highlights the value of leveraging personal narratives to drive policy change and fundraising.

What we're watching

Geopolitical Impact
The continued expansion of Breakthrough T1D’s global outreach, particularly in regions with limited healthcare infrastructure, may require navigating complex regulatory and logistical challenges.
Succession Risk
The passing of Princess Padmaja's father, a key supporter, introduces a potential succession risk for her advocacy efforts and the programs she champions.
Policy Shifts
The organization’s ability to maintain influence with US policymakers will depend on the evolving political landscape and the prioritization of healthcare initiatives.

Breakthrough T1D CMO Award Signals Focus on Therapy Adoption

Event summary

  • Dr. Thomas Danne, CMO of Breakthrough T1D, is receiving the Children with Diabetes President's Award for Innovation.
  • The award will be presented on March 13, 2026, at the Advanced Technologies & Treatment for Diabetes conference in Barcelona.
  • Dr. Danne previously held leadership positions at Hannover Medical School and the SWEET Registry.
  • Breakthrough T1D (formerly JDRF) focuses on T1D research, advocacy, and improving access to therapies.
  • Type 1 Diabetes impacts 9.5 million people globally, with nearly 50% of diagnoses occurring in adulthood.

The big picture

The recognition of Dr. Danne highlights Breakthrough T1D's strategic pivot towards not only research but also the practical implementation and adoption of new therapies. This focus on access and adoption is critical given the high cost of T1D treatment and the ongoing need for improved patient outcomes. The award underscores the importance of clinical leadership in driving the organization's mission and navigating the complex landscape of diabetes care.

What we're watching

Adoption Rate
How Breakthrough T1D will leverage Dr. Danne's expertise to accelerate the adoption of new therapies among patients and clinicians remains to be seen, given the challenges of reimbursement and patient education.
SWEET Registry
The legacy of Dr. Danne's 16-year leadership of the SWEET Registry and its impact on data collection and quality of care will be a key indicator of his influence within the organization.
Global Reach
Whether Breakthrough T1D will expand its global initiatives, particularly in regions where access to advanced diabetes care is limited, given Dr. Danne's international experience, warrants observation.

Breakthrough T1D Honors Volunteers, Highlights Advocacy Impact

Event summary

  • Breakthrough T1D (formerly JDRF) presented five awards at its annual One Conference on February 26, 2026, in New Orleans.
  • Pete Cerar led the restructuring of Northern Ohio Chapter boards, improving focus and growth opportunities.
  • Deborah Nuzzo spearheaded a gala revenue increase of 300% in 2017 and facilitated a chapter merger.
  • Matt Varey, the first non-US member of the International Board, led a cross-Canada fundraising ride.
  • Larry Soler’s advocacy efforts have secured over $2 billion in federal funding for T1D research.

The big picture

Breakthrough T1D's reliance on volunteer efforts highlights the challenges and opportunities inherent in non-profit governance and fundraising. The recognition of Mattel’s partnership underscores the growing importance of corporate social responsibility and brand alignment in driving awareness and support for charitable causes. The organization's global expansion strategy signals an ambition to broaden its impact beyond North America, requiring careful navigation of diverse cultural and regulatory environments.

What we're watching

Volunteer Retention
The organization's reliance on volunteer leadership, as exemplified by these awards, necessitates a focus on retention strategies to ensure continuity and expertise.
Global Expansion
Matt Varey's leadership in international expansion suggests Breakthrough T1D will continue to prioritize global outreach, potentially requiring adjustments to governance and resource allocation.
Advocacy Impact
Larry Soler’s past advocacy successes indicate a continued emphasis on legislative influence, which may be subject to shifting political landscapes and regulatory hurdles.

SanMar Sponsorship Signals Growing Corporate Investment in T1D Research

Event summary

  • Breakthrough T1D (formerly JDRF) launched its 2026 Walks to raise funds and awareness for Type 1 Diabetes (T1D) research.
  • SanMar Corporation, led by CEO Jeremy Lott, is a National Series sponsor, building on a $2.7 million contribution in 2025.
  • Over 120 Walks are planned across the U.S., engaging individuals, families, and corporate sponsors.
  • T1D affects 9.5 million people globally, with nearly 50% of diagnoses occurring in adulthood.

The big picture

The continued reliance on corporate sponsorships like SanMar's underscores the challenges in securing consistent funding for non-profit research organizations. While the Walks generate significant revenue, the organization's long-term sustainability depends on cultivating and expanding these partnerships. The personal connection of leadership, like Jeremy Lott's, highlights the power of emotional investment in driving philanthropic support.

What we're watching

Sponsorship Trends
The level of corporate commitment from SanMar, and potentially Ford, suggests a growing willingness to invest in T1D research, which could influence future fundraising strategies for Breakthrough T1D and similar organizations.
Employee Engagement
SanMar's employee participation, highlighted by Nick Anderson's involvement, indicates a potential for leveraging employee engagement programs to drive fundraising and brand awareness, a model other companies may emulate.
Research Funding
The success of the Walks will directly impact Breakthrough T1D's ability to fund research initiatives, and the organization's progress towards a cure will be inextricably linked to continued fundraising success.

Land O'Frost Commits $2M+ to T1D Research in National Partnership

Event summary

  • Land O'Frost has expanded its existing partnership with Breakthrough T1D (formerly JDRF) to a national level.
  • The partnership builds on over 17 years of Land O'Frost's support, totaling over $2 million in contributions to T1D research.
  • Land O'Frost CEO David Van Eekeren's personal connection to T1D (his son lives with the condition) has been a driving force behind the company's involvement.
  • Breakthrough T1D is focused on research, advocacy, and education related to Type 1 Diabetes, impacting 9.5 million people globally.

The big picture

This national partnership highlights a growing trend of corporations aligning their brand image and CSR initiatives with specific health-related causes. While Land O'Frost's $2 million contribution is significant, it represents a small fraction of the overall funding needed for T1D research, indicating ongoing reliance on diverse funding sources. The partnership's success will depend on both organizations' ability to deliver measurable impact and maintain a consistent narrative around their shared mission.

What we're watching

Financial Impact
The scale of Land O'Frost's national partnership suggests a sustained and potentially increasing level of financial commitment to Breakthrough T1D, which could influence the organization's research pipeline and advocacy efforts.
Brand Alignment
Land O'Frost's CSR report and public statements highlight a focus on quality and sustainability; the partnership's success will depend on how effectively Breakthrough T1D aligns with these values to avoid reputational risk.
Research Progress
The timing of the partnership announcement, coinciding with anticipated breakthroughs in T1D research, suggests Breakthrough T1D will be under pressure to demonstrate tangible progress and justify Land O'Frost's investment.

Ford Charity Auction Drives $1.25M to Type 1 Diabetes Research

Event summary

  • Ford Motor Company auctioned the first Ford Mustang Dark Horse SC at Barrett-Jackson Scottsdale.
  • The auction generated $1.25 million in proceeds.
  • All proceeds were donated to Breakthrough T1D (formerly JDRF).
  • Breakthrough T1D has partnered with Ford for decades, raising over $85 million since 1998.
  • The auction was part of a larger event featuring nine charity cars.

The big picture

This donation highlights the increasing trend of automakers leveraging limited-edition vehicles for charitable fundraising. While $1.25 million is a significant contribution, it represents a small fraction of Ford’s annual revenue, suggesting the partnership is more about brand image and corporate social responsibility than a material financial impact on Breakthrough T1D’s overall budget. The continued reliance on corporate philanthropy underscores the ongoing funding challenges facing non-profits focused on rare diseases.

What we're watching

Partnership Sustainability
The long-standing nature of the Ford/Breakthrough T1D partnership suggests a deeper alignment, but future funding levels will depend on Ford’s overall philanthropic strategy and economic performance.
Auction Dynamics
The high value of the Mustang Dark Horse SC auction indicates strong demand for unique assets linked to charitable causes, potentially influencing future fundraising strategies for both Ford and Breakthrough T1D.
Research Impact
The substantial donation will accelerate Breakthrough T1D’s research pipeline, but the organization’s ability to translate these funds into tangible therapeutic advancements will be a key determinant of long-term success.

Breakthrough T1D Funds Virtual Care Expansion Amid Healthcare Coverage Shifts

Event summary

  • Breakthrough T1D (formerly JDRF) awarded Blue Circle Health a $1.5 million, three-year grant.
  • The grant aims to improve insurance navigation and continuity of care for adults with Type 1 Diabetes (T1D).
  • Blue Circle Health provides free, virtual care and support services for adults with T1D.
  • The funding responds to increasing challenges related to Medicaid and Affordable Care Act coverage changes.
  • Adults account for nearly 50% of all T1D diagnoses globally.

The big picture

The grant highlights the growing intersection of healthcare access, insurance coverage volatility, and the needs of individuals with chronic conditions like Type 1 Diabetes. Changes to government healthcare programs are creating significant barriers to care, particularly for vulnerable populations, and organizations like Breakthrough T1D are increasingly directing resources to address these gaps. The virtual care model employed by Blue Circle Health represents a potential solution for expanding access, but its long-term viability depends on sustained funding and demonstrated effectiveness.

What we're watching

Policy Impact
Future Medicaid and Affordable Care Act policy changes will likely continue to drive demand for services like those offered by Blue Circle Health, potentially impacting grant funding needs and program scalability.
Care Model
The success of Blue Circle Health’s community-centered, virtual care model will be a key indicator of whether this approach can effectively address the challenges faced by underserved T1D patients.
Funding Sustainability
Breakthrough T1D’s reliance on grants to support critical care services raises questions about the long-term financial sustainability of these programs and potential diversification of funding sources.
CID: 454